Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBIT (2018 - 2025)

Addex Therapeutics' EBIT history spans 8 years, with the latest figure at -$974990.3 for Q4 2025.

  • On a quarterly basis, EBIT rose 69.0% to -$974990.3 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.4 million, a 40.89% increase, with the full-year FY2025 number at -$3.4 million, down 7.94% from a year prior.
  • EBIT came in at -$974990.3 for Q4 2025, down from -$870295.0 in the prior quarter.
  • The five-year high for EBIT was -$397495.9 in Q1 2023, with the low at -$21.3 million in Q4 2022.
  • Historically, EBIT has averaged -$4.1 million across 5 years, with a median of -$1.8 million in 2023.
  • Biggest five-year swings in EBIT: soared 94.02% in 2023 and later plummeted 127.15% in 2024.
  • Year by year, EBIT stood at -$16.8 million in 2021, then dropped by 26.66% to -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then decreased by 24.37% to -$3.1 million in 2024, then soared by 69.0% to -$974990.3 in 2025.
  • Business Quant data shows EBIT for ADXN at -$974990.3 in Q4 2025, -$870295.0 in Q3 2025, and -$885260.3 in Q2 2025.